Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BupiZenge vs Lidocaine for Oral Mucositis Pain in Head and Neck Cancer
NCT07672236Phase 3Recruiting
- Sponsor
- OncoZenge
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 4
01
Overview
A Phase 3 trial of bupivacaine + benzydamine in oral mucositis (OM), sponsored by OncoZenge. Started Jul 2026; status: recruiting.
02
Drugs
bupivacaine + benzydamine
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT07672236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672236.